PERBANDINGAN RESPON AWAL PEMBERIAN WARFARIN PADA PASIEN OBESITAS DAN NON OBESITAS DI RSUP DR. SARDJITO YOGYAKARTA

D. Oktianti, S. I Dewa Putu Pramantara S.
{"title":"PERBANDINGAN RESPON AWAL PEMBERIAN WARFARIN PADA PASIEN OBESITAS DAN NON OBESITAS DI RSUP DR. SARDJITO YOGYAKARTA","authors":"D. Oktianti, S. I Dewa Putu Pramantara S.","doi":"10.22146/JMPF.366","DOIUrl":null,"url":null,"abstract":"Warfarin oral anticoagulant is most prescribed in the world. Warfarin is\nprescribed for prevention of thromboembolic event, associated with atrial\nfibrillation, prosthetic heart valves, or history of vascular thrombosis. Variability\nin warfarin dose because of the variation among the patient and therapeutic\nresponse depend on age, influence of another disease, nutritional status, weight,\nconcomitant medicine, influence of genetic polymorphism of the CYP2C9 or\nVKORC1. Optimal dose warfarin can be monitored with international normalized\nratio (INR). The aims of this study is to compare initial warfarin response between\nobese and non obese patient at RSUP dr. Sardjito Yogyakarta.\nThis study was a retrospective with design descriptive observational study.\nSubject in research is outpatient that receive newly warfarin therapy and with\ncomplete INR value. To determine time required to achieve a therapeutic INR was\nanalyzed using non parametric test with Kaplan-Meier method.\nThe result of this study, 92 patient were included. Patient distribution were 44\npatient with obesity and 48 patient with normal weight. Based on Kaplan-Meier\nanalyzed the median time to achieve therapeutic INR in obese patient is 56 days\nand in normal weight is 57 days with p=0,316 (p>0,05) there is no significant\ndifference between the group.\nKey word: Warfarin, Obese, non obese, INR, time to achieve therapeutic INR","PeriodicalId":125871,"journal":{"name":"Journal of Management and Pharmacy Practice","volume":"6 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Management and Pharmacy Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22146/JMPF.366","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Warfarin oral anticoagulant is most prescribed in the world. Warfarin is prescribed for prevention of thromboembolic event, associated with atrial fibrillation, prosthetic heart valves, or history of vascular thrombosis. Variability in warfarin dose because of the variation among the patient and therapeutic response depend on age, influence of another disease, nutritional status, weight, concomitant medicine, influence of genetic polymorphism of the CYP2C9 or VKORC1. Optimal dose warfarin can be monitored with international normalized ratio (INR). The aims of this study is to compare initial warfarin response between obese and non obese patient at RSUP dr. Sardjito Yogyakarta. This study was a retrospective with design descriptive observational study. Subject in research is outpatient that receive newly warfarin therapy and with complete INR value. To determine time required to achieve a therapeutic INR was analyzed using non parametric test with Kaplan-Meier method. The result of this study, 92 patient were included. Patient distribution were 44 patient with obesity and 48 patient with normal weight. Based on Kaplan-Meier analyzed the median time to achieve therapeutic INR in obese patient is 56 days and in normal weight is 57 days with p=0,316 (p>0,05) there is no significant difference between the group. Key word: Warfarin, Obese, non obese, INR, time to achieve therapeutic INR
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
日惹临床对肥胖和非肥胖患者的反应比较
华法林口服抗凝剂是世界上开得最多的。华法林用于预防与心房颤动、人工心脏瓣膜或血管血栓形成史相关的血栓栓塞事件。患者之间华法林剂量的变异性取决于年龄、其他疾病的影响、营养状况、体重、伴随用药、CYP2C9或vkorc1基因多态性的影响。华法林最佳剂量可用国际标准化比值(INR)监测。本研究的目的是比较RSUP dr. Sardjito Yogyakarta的肥胖和非肥胖患者对华法林的初始反应。本研究为回顾性设计描述性观察性研究。研究对象为接受华法林新治疗且INR值完整的门诊患者。为了确定达到治疗性INR所需的时间,采用Kaplan-Meier法进行非参数检验。本研究结果纳入92例患者。患者分布:肥胖44例,体重正常48例。根据kaplan - meier分析,肥胖患者达到治疗性INR的中位时间为56天,正常体重患者为57天,p=0,316 (p> 0.05),两组间差异无统计学意义。关键词:华法林,肥胖,非肥胖,INR,达到治疗INR时间
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Measurement of Medication Adherence Behavior in Type 2 Diabetes Mellitus Patients Using Probabilistic Medication Adherence Scale (ProMAS) GAMBARAN KEPATUHAN PENGGUNAAN OBAT ANTITUBERKULOSIS PADA PASIEN TUBERKULOSIS PARU DI PUSKESMAS PAHANDUT KOTA PALANGKARAYA Analisis Medication Error di Instalasi Farmasi Rawat Jalan RSPAD Gatot Soebroto Jakarta Pusat SYSTEMATIC REVIEW DAN META-ANALISIS : ANALISIS DAMPAK INTERVENSI APOTEKER TERHADAP CLINICAL OUTCOME PASIEN EPILEPSI Rasionalitas Terapi Antibotik Empiris Pada Pasien Geriatri Dengan Pneumonia Di RS Mardi Rahayu
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1